human
The task is to decide the Hallmarks of Cancer (HOC) taxonomy of the article based on its abstract. The input is an abstract text. There are 10 topics you will need to decide whether the article is related to. Topics: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, genomic instability and mutation, tumor promoting inflammation, cellular energetics, avoiding immune destruction. The output should be topics from the above 10 topics, that are related to the input article. Please note one article can be related to multiple topics. Output format: provide a semicolon-separated list of relevant topics.
    ###
    INPUT: Hormone antagonist therapy for estrogen receptor positive ( ER+ ) breast cancer patients post radical surgery and radiation therapy has a poor prognosis and also causes bone loss. 1Î±,25-dihydroxyvitamin D(3) [ 1Î±,25(OH)(2)D(3) ] is a potent antitumor agent in pre-clinical studies , but caused hypercalcemia when its effective antitumor doses were used . Therefore , we investigated the effects of a less-calcemic 1Î±,25(OH)(2)D(3) analog , 19-nor-2Î±-(3-hydroxypropyl)-1Î±,25-dihydroxyvitamin D(3 )(MART-10 ) , on ER+MCF-7 cells . We demonstrate that MART-10 is 500- to 1000-fold more potent than 1Î±,25(OH)(2)D(3) in inhibiting cell growth in a dose- and time-dependent manner . MART-10 is also much more potent in arresting MCF-7cell cycle progression at G(0)/G(1) phase as compared to 1Î±,25(OH)(2)D(3) , possibly mediated by a greater induction of p21 and p27 expression . Moreover , MART-10 is more active than 1Î±,25(OH)(2)D(3) in causing cell apoptosis , likely through a higher BAX/Bcl expression ratio and the subsequent cytochrome C release from mitochondria to cytosol . Based on our in vitro findings , MART-10 could be a promising vitamin D analog for the potential treatment of breast cancer , for example , ER+ patients , to decrease the tumor relapse rate and the side effect on bone caused by antihormone regimens . Thus , further in vivo animal study is warranted .
    OUTPUT:

agent
evading growth suppressors;sustaining proliferative signaling;resisting cell death
The task is to decide the Hallmarks of Cancer (HOC) taxonomy of the article based on its abstract. The input is an abstract text. There are 10 topics you will need to decide whether the article is related to. Topics: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, genomic instability and mutation, tumor promoting inflammation, cellular energetics, avoiding immune destruction. The output should be topics from the above 10 topics, that are related to the input article. Please note one article can be related to multiple topics. Output format: provide a semicolon-separated list of relevant topics.
    ###
    INPUT: Hormone antagonist therapy for estrogen receptor positive ( ER+ ) breast cancer patients post radical surgery and radiation therapy has a poor prognosis and also causes bone loss. 1Î±,25-dihydroxyvitamin D(3) [ 1Î±,25(OH)(2)D(3) ] is a potent antitumor agent in pre-clinical studies , but caused hypercalcemia when its effective antitumor doses were used . Therefore , we investigated the effects of a less-calcemic 1Î±,25(OH)(2)D(3) analog , 19-nor-2Î±-(3-hydroxypropyl)-1Î±,25-dihydroxyvitamin D(3 )(MART-10 ) , on ER+MCF-7 cells . We demonstrate that MART-10 is 500- to 1000-fold more potent than 1Î±,25(OH)(2)D(3) in inhibiting cell growth in a dose- and time-dependent manner . MART-10 is also much more potent in arresting MCF-7cell cycle progression at G(0)/G(1) phase as compared to 1Î±,25(OH)(2)D(3) , possibly mediated by a greater induction of p21 and p27 expression . Moreover , MART-10 is more active than 1Î±,25(OH)(2)D(3) in causing cell apoptosis , likely through a higher BAX/Bcl expression ratio and the subsequent cytochrome C release from mitochondria to cytosol . Based on our in vitro findings , MART-10 could be a promising vitamin D analog for the potential treatment of breast cancer , for example , ER+ patients , to decrease the tumor relapse rate and the side effect on bone caused by antihormone regimens . Thus , further in vivo animal study is warranted .
    OUTPUT:
